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Abstract
Background: Prostate cancer that has recurred after local therapy or disseminated distantly is usually treated with
androgen deprivation therapy; however, most men will eventually experience disease progression within 12 to 20
months. New data emerging from randomized controlled trials (RCTs) of chemotherapy provided the impetus for a
systematic review addressing the following question: which non-hormonal systemic therapies are most beneficial for the
treatment of men with hormone-refractory prostate cancer (HRPC) and clinical evidence of metastases?
Methods: A systematic review was performed to identify RCTs or meta-analyses examining first-line non-hormonal
systemic (cytotoxic and non-cytotoxic) therapy in patients with HRPC and metastases that reported at least one of the
following endpoints: overall survival, disease control, palliative response, quality of life, and toxicity. Excluded were RCTs
of second-line hormonal therapies, bisphosphonates or radiopharmaceuticals, or randomized fewer than 50 patients per
trial arm. MEDLINE, EMBASE, the Cochrane Library, and the conference proceedings of the American Society of Clinical
Oncology were searched for relevant trials. Citations were screened for eligibility by four reviewers and discrepancies
were handled by consensus.
Results: Of the 80 RCTs identified, 27 met the eligibility criteria. Two recent, large trials reported improved overall
survival with docetaxel-based chemotherapy compared to mitoxantrone-prednisone. Improved progression-free survival
and rates of palliative and objective response were also observed. Compared with mitoxantrone, docetaxel treatment
was associated with more frequent mild toxicities, similar rates of serious toxicities, and better quality of life. More
frequent serious toxicities were observed when docetaxel was combined with estramustine. Three trials reported
improved time-to-disease progression, palliative response, and/or quality of life with mitoxatrone plus corticosteroid
compared with corticosteroid alone. Single trials reported improved disease control with estramustine-vinblastine,
vinorelbine-hydrocortisone, and suramin-hydrocortisone compared to controls. Trials of non-cytotoxic agents have
reported equivocal results.
Conclusion: Docetaxel-based chemotherapy modestly improves survival and provides palliation for men with HRPC
and metastases. Other than androgen deprivation therapy, this is the only other therapy to have demonstrated improved
overall survival in prostate cancer in RCTs. Further investigations to identify more effective therapies for HRPC including
the use of systemic therapies earlier in the natural history of prostate cancer are warranted.
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Prostate cancer is the most frequently diagnosed cancer in
North America, and the third most common cause of can-
cer death in men [1]. Men with prostate cancer that has
recurred after local therapy or disseminated distantly usu-
ally respond to androgen deprivation therapy (ADT).
However, most patients eventually experience disease
progression within a median of 12 to 20 months [2].
Androgen independence is defined as disease progression
despite effective ADT, typically first identified by a rise in
serum prostatic-specific antigen (PSA) levels. Hormone-
refractory prostate cancer (HRPC) arises when disease
progression continues despite secondary hormonal
maneuvers and antiandrogen withdrawal (AAWD). The
prognosis of HRPC is associated with performance status,
the presence of bone pain, extent of disease on bone scan,
and serum alkaline phosphatase levels [3]. Bone metas-
tases will occur in 90% of men with HRPC and can pro-
duce significant morbidity including pain, pathologic
fractures, spinal cord compression, and bone marrow fail-
ure [4]. Paraneoplastic effects are also common, including
anemia, weight loss, fatigue, hypercoagulability, and
increased susceptibility to infection. Thus, HRPC presents
a spectrum of disease ranging from patients without
metastases or symptoms with rising PSA levels despite
ADT, to patients with metastases and significant debilita-
tion due to cancer symptoms. Historically, clinical man-
agement has been primarily palliative with a focus on
expectant management when possible and palliative
interventions such as radiotherapy, radioisotopes, and
chemotherapy when necessary [5]. New data emerging
from large clinical trials of chemotherapy provided the
impetus for this systematic review of the value of chemo-
therapy and other non-hormonal agents in HRPC.
Methods
Development of systematic review
The Genitourinary Cancer Disease Site Group of the Can-
cer Care Ontario Program in Evidence-Based Care
(CCOPEBC) has developed an evidence-based clinical
practice guideline on the use of non-hormonal systemic
therapy for HRPC using the methodology outlined in the
practice guideline development cycle by Browman et al
[6]. The guideline was derived from a systematic review
and input from practitioners in Ontario, Canada. This
report describes the systematic review portion of the
guideline, which addressed the following question: which
non-hormonal systemic therapies are most beneficial for
the treatment of men with HRPC and clinical evidence of
metastases?
Inclusion criteria
Articles were selected for inclusion in the systematic
review if they were randomized controlled trials (RCTs) or
meta-analyses of RCTs studying a first-line non-hormonal
systemic (cytotoxic and non-cytotoxic) therapy in patients
with HRPC and metastases that reported on at least one of
the following outcomes: overall survival, disease control
(i.e., progression-free survival [PFS], time-to-progression
[TTP], time-to-treatment failure, objective tumor
response, and PSA response), palliative or symptomatic
response, quality of life (QoL), and/or toxicity. Previous
systematic reviews or evidence-based guidelines that
addressed non-hormonal systemic therapy in HRPC were
also eligible for inclusion.
Exclusion criteria
Articles were excluded from the systematic review if they
studied second-line hormonal therapies, bisphospho-
nates or radiopharmaceuticals, or randomized fewer than
50 patients per trial arm. When formulating the protocol
for this review, the authors were aware of dozens of small
randomized trials comparing the activity of various drugs
in HRPC. Sometimes these were identified explicitly as
phase II trials, but often they were not. Although valuable
for identifying potential anti-tumor activity, such trials are
by definition underpowered to address the patient out-
comes of interest to this review, and often did not report
these. Although these limitations could be overcome by
statistical pooling, it is also recognized that such RCTs are
associated with more variability and are more likely to be
reported and published if positive [7]. Theoretically, pos-
itive results from such trials require subsequent confirma-
tion by larger pragmatic RCTs, but this does not always
occur. After considering the outcomes of interest for this
review, a minimum sample size of 50 randomized
patients per trial arm was chosen, in order to be as inclu-
sive as possible while still minimizing inclusion of rand-
omized phase II trials. This sample size was based on a
requirement of at least 80% power for an RCT to reliably
detect the difference between an endpoint response rate of
10% versus 30% with one-tailed α = 0.05. Reliable assess-
ment of outcomes such as disease-free and overall survival
would require even larger sample sizes. RCTs with lesser
discriminating ability were considered underpowered and
potentially misleading with regard to those endpoints.
Literature search strategy
The MEDLINE (1966 through March 2004), EMBASE
(1980 through 2004, week 10), and Cochrane Library
(2003, Issue 4) databases (Central Register of Controlled
Trials [CCTR] and Database of Systematic Reviews [DSR]),
and the conference proceedings of the American Society
of Clinical Oncology (1999 through 2004) were searched
for abstracts of relevant trials. MEDLINE was searched
using the following medical subject headings (MeSH):
"prostatic neoplasms", "drug therapy", "antineoplastic
agents", and "drug therapy, combination"; and EMBASE
was searched using the following Excerpta Medica tree
terms: "prostate tumor", "prostate cancer", "drug ther-Page 2 of 18
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"combination chemotherapy". In each database, those
subject headings were combined with disease and treat-
ment-specific text words (e.g., "prostate cancer", "prostate
tumor", "prostate carcinoma", and "chemotherapy").
Those terms were then combined with the search terms
for the following publication types and study designs:
practice guidelines, systematic reviews, meta-analyses,
reviews, randomized controlled trials, and controlled
clinical trials. The CCTR and DSR databases were searched
using a combination of the aforementioned MeSH and
keywords. The reference lists from eligible articles were
searched for additional trials, as were the reference lists
from relevant review papers.
Methods of review
Citations identified by the literature search strategy were
screened for eligibility by four of the authors (EW, DSE,
SB, SH) and discrepancies were handled by consensus.
Data pertaining to trial design, participants, interventions,
and outcomes were extracted from each eligible trial by
one reviewer (TW) and were audited by a second reviewer
(EW) independently. Information indicative of trial qual-
ity, including methods of randomization, absence or
degree of blinding, completeness of patient follow-up,
and whether statistical analyses were performed by intent-
to-treat were also extracted from each trial report. The
quality parameters assessed on each trial were used to
identify any trials with serious flaws in trial methodology
that could lead to potentially misleading results.
Synthesis of the evidence
This review is based on data provided by published
reports. When pooling of data is to be undertaken and
individual patient data are not available, methods are
available for generating summary statistics from pub-
lished data. However, statistical pooling (meta-analysis)
of data from RCTs is only possible if control arms are sim-
ilar and is only valid if those data are statistically homoge-
neous. Reports of RCTs studying systemic therapies in
HRPC date back 30 years and have studied heterogeneous
patient populations, interventions, and outcomes.
Numerous drug interventions have been tested, including
a variety of single-agent and combination chemotherapy
regimens including estramustine phosphate (EMP), and
non-cytotoxic drugs such as liarazole, suramin, and
atrasentan. What constitutes standard therapy in control
arms has been controversial and has included placebo,
corticosteroids, EMP, and cytotoxics. On the basis of those
observations, large-scale quantitative pooling of RCT data
was considered neither possible nor appropriate, and so
an interpretive summary of the data was planned. The nat-
ural history and management of HRPC has changed in the
last three decades; therefore, more contemporary studies
were emphasized in the interpretive summary to provide
clinicians with the evidence most relevant to current prac-
tice. Furthermore, more emphasis on the results of RCTs
demonstrating internally consistent benefits in survival,
palliation, and quality of life outcomes was planned.
Results
Literature search results
The literature search identified 80 unique RCTs that com-
pared non-hormonal systemic treatments in HRPC. Fifty-
three of those trials randomized less than 50 patients per
arm and were considered ineligible [8-60] (see Additional
file 1). Of the 27 eligible trials, 22 were published as full
reports [61-83], and five were available only in abstract or
poster presentation form but provided adequate data on
at least one outcome of interest [84-88]. There were 21
two-arm and six three-arm trials, and two trials were
labeled as randomized phase II reports [79,84]. No pub-
lished systematic reviews or evidence-based guidelines
were identified. No trials were excluded due to their qual-
ity.
The 27 RCTs that form the basis of this review were pub-
lished between 1979 and 2004. A total of 7489 eligible
men were randomized, ranging from 102 to 1006 per
RCT. Six trials were placebo-controlled [65,79,82,85-87],
and four of those were also double-blinded [65,79,82,85].
Twelve trials described the methods used to randomize
patients [61-65,70-73,79,83,86], and 21 reported that
treatment arms were balanced for important baseline
prognostic factors [61-67,69-73,75-79,81-83,87]. Twelve
trials performed statistical analyses according to intent-to-
treat [62-64,70,71,74,79,81-83,85,86]. A minority of tri-
als reported whether patients underwent AAWD [61-
64,69-71,79,81,83] and continued to receive ADT during
the study period [61-64,69-71,81-83]. Twenty trials stud-
ied cytotoxic [61-78,84,88] and seven studied non-cyto-
toxic drug interventions [79-83,85-87]. Two cytotoxic
trials studied agents belonging to multiple drug classes
[75,88]. For clarity, the cytotoxic trials have been organ-
ized according to the drug class tested by the trial: antimi-
crotubule-based regimens (nine trials),
anthracendedione/anthracycline-based regimens (nine
trials), and other chemotherapy (four trials).
Antimicrotubule-based chemotherapy
Docetaxel
Docetaxel induces polymerization of microtubules and
phosphorylation of bcl-2 protein. Two large RCTs com-
paring docetaxel-based chemotherapy to mitoxantrone-
prednisone have recently been published (Table 1). Tan-
nock et al [64] randomized 1006 patients to one of three
treatment arms: docetaxel (75 mg/m2 intravenously [iv]
every [q] three weeks), docetaxel (30 mg/m2 iv five-times
weekly for five of six weeks), or control therapy with
mitoxantrone. Patients in all three arms also receivedPage 3 of 18
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[63] reported on 666 eligible patients randomized to
docetaxel and EMP or mitoxantrone-prednisone. In addi-
tion to dexamethasone premedication, patients in the
docetaxel arm also received warfarin and acetylsalicylic
acid (ASA) as thrombosis prophylaxis during the course of
the trial. Men in both trials had clinical evidence of metas-
tases with or without symptoms and had undergone
AAWD. Overall survival was the primary endpoint in both
trials.
Tannock et al [64] reported improved survival with
docetaxel-prednisone (q third week) compared with
mitoxantrone-prednisone (median survival, 18.9 versus
16.5 months; hazard ratio [HR] = 0.76 [95% confidence
interval (CI), 0.62–0.94], two-sided p = 0.009) (Table 2).
No overall survival benefit was observed with docetaxel-
prednisone given on a weekly schedule (HR = 0.91, [95%
CI, 0.75–1.11], two-sided p = 0.36). Petrylak et al [63]
reported longer survival time with docetaxel-EMP combi-
nation chemotherapy compared with mitoxantrone-pred-
nisone (median survival, 17.5 versus 15.6 months; HR =
0.80 [95% CI, 0.67–0.97], two-sided p = 0.02) (Table 2).
This trial also reported a median progression-free interval
of 6.3 versus 3.2 months (HR = 0.73 [95% CI, 0.63–0.86],
two-sided p < 0.0001) favoring docetaxel-EMP compared
with mitoxantrone-prednisone.
Pain response was assessed in both trials. Significantly
more patients treated with docetaxel-prednisone (q third
week) achieved a pain response compared with patients
receiving mitoxantrone-prednisone (35% versus 22%, p =
0.01) [64]. A trend towards improved pain response was
observed with weekly docetaxel-prednisone versus mitox-
antrone-prednisone (31% versus 22%, p = 0.08). QoL
response defined as a sustained 16-point or greater
improvement from baseline on two consecutive measure-
ments was higher with docetaxel given every three weeks
(22% versus 13%, p = 0.009) or weekly (23% versus 13%,
p = 0.005) compared with mitoxantrone. Petrylak et al
Table 1: Antimicrotubule trials.
Trial N randomized/evaluable Treatment arms (dose) and schedule Duration
Tannock, 2004 [64] 1006/1006 docetaxel (75 mg/m2) iv q 3 wks prednisone (5 mg) po 
twice daily dexamethasone (8 mg) at 12, 3, and 1 hr(s) 
prior to infusion
10 cycles
docetaxel (30 mg/m2) iv q wk for 5 wks prednisone (5 mg) 
po twice daily dexamethasone (8 mg) at 1 hr prior to 
infusion
5 cycles
mitoxantrone (12 mg/m2) iv q 3 wks prednisone (5 mg) po 
twice daily
10 cycles
Petrylak, 2004 [63] 770/666 docetaxel (60 mg/m2)* iv q 3 wks EMP (280 mg) po thrice 
daily q 3 wks dexamethasone (20 mg) po thrice daily q 3 
wks
12 cycles
mitoxantrone (12 mg/m2)* iv q 3 wks prednisone (5 mg) 
po twice daily q 3 wks
Abratt, 2003 [62] 451/414 vinorelbine (30 mg/m2) iv q 3 wks hydrocortisone (40 mg) 
± AGM (1000 mg)† daily
to progression
hydrocortisone (40 mg) ± AGM (1000 mg)† daily
Berry, 2001 [84] 166/NR paclitaxel (100 mg/m2) iv q 4 wks EMP (280 mg) po thrice 
daily
NR
paclitaxel (100 mg/m2) iv q 4 wks
Hudes, 1999 [61] 201/193 vinblastine (4 mg/m2) iv q wk for 6 of 8 wks EMP (600 mg/
m2) po daily (2 or 3 divided doses)
to progression
vinblastine (4 mg/m2) iv q wk for 6 of 8 wks
Iversen, 1997 [65] 131/129 EMP (560 mg) po daily (2 divided doses) as long as tolerated by patient
placebo po daily
Johansson, 1991 [66] 105/102 MPA (1000 mg) im daily (d1-15), then im weekly to progression
EMP (280 mg) po twice daily
De Kernion, 1988 [67] 220/203 EMP (600 mg/m2) po (3 divided doses) NR
flutamide (0.25 gm) po thrice daily
Murphy, 1979 [68] 135/116 EMP (600 mg/m2) po daily (3 divided doses) prednimustine 
(30 mg) po daily (3 divided doses) q wk
to progression
prednimustine (30 mg) po daily (3 divided doses) q wk
*Docetaxel could be increased to 70 mg/m2 and mitoxantrone could be increased to 14 mg/m2 if no grade 3 or 4 toxicities were observed in cycle 
1; †decision to use AGM was at the discretion of participating centers.
Abbreviations: AGM – aminoglutethimide; d – day; EMP – estramustine phosphate; hr – hour; im – intra muscular; iv – intravenous; mg – milligrams; 
MPA – medroxyprogesterone acetate; m2 - meters squared; N – number; NR – not reported; po – per oral; q – every; wk(s) – week (s).Page 4 of 18
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between arms in their trial and did not assess QoL.
In both trials, PSA response rates were also statistically sig-
nificantly higher with docetaxel compared to mitox-
antrone (Table 3). Twenty-seven per cent (n = 412) [64]
and 29% (n = 196) [63] of patients in the two trials had
measurable disease. Objective response rates for
docetaxel-prednisone (q three weeks) and mitoxantrone-
prednisone were 12% versus 7%, respectively (Table 3).
Petrylak et al [63] reported objective response rates of
17% and 11% favoring docetaxel-EMP compared with
mitoxantrone-prednisone. The differences in objective
response rates between arms were not statistically signifi-
cant in either trial.
More grade 3–4 neutropenia (32% and 22% versus 1.5%)
and neutropenic infection (3% and 0.9% versus 0%) were
observed with docetaxel-prednisone (q third week) com-
pared with mitoxantrone-prednisone and docetaxel-pred-
nisone given weekly, respectively [64]. However, only two
septic deaths occurred, one each in the mitoxantrone and
weekly docetaxel arms. Grade 3–4 non-hematological tox-
icities were infrequent and similar in the docetaxel and
mitoxantrone arms. Mild to moderate alopecia, fatigue,
diarrhea, nail changes, stomatitis, peripheral edema, ano-
rexia, and dyspnea were more common with docetaxel.
More grade 3–4 toxicity (53% versus 33%) was associated
with docetaxel-EMP compared with mitoxantrone-pred-
nisone, primarily due to higher rates of gastrointestinal
and cardiovascular events [63]. The protocol was
amended to add oral coumadin (2 mg daily) and oral ASA
(325 mg daily) to the docetaxel arm, but post hoc analysis
suggested prophylactic anticoagulation had little effect on
the rate of thromboembolic events. Docetaxel-EMP was
also associated with statistically significantly higher rates
of metabolic disturbances (6% versus 1%) and neurologic
events (7% versus 2%) compared to mitoxantrone-pred-
Table 2: Antimicrotubule trials: survival outcomes.
Trial Treatment arms Overall survival Progression-free survival or TTP
N Median (mo) Statistical 
comparison
N Median (mo) Statistical 
comparison
Tannock, 2004 [64] docetaxel q 3 wks 
prednisone




docetaxel q wk prednisone 334 17.4 HR = 0.91
(95% CI, 0.75–1.11)
p = 0.36
Mitoxantrone prednisone 337 16.5 NA
Petrylak, 2004 [63] Docectaxel EMP 338 17.5 HR = 0.80
(95% CI, 0.67–0.97)
p = 0.02
324 6.3 HR = 0.73
(95% CI, 0.63–0.86) 
p < 0.001 (TPP)
Mitoxantrone prednisone 336 15.6 324 3.2
Abratt, 2004 [62] Vinorelbine hydrocortisone 
± AGM
206 14.7 p = 0.95 206 3.7 HR = 0.71
p = 0.055 
(unadjusted)
p = 0.005 
(adjusted)*
hydrocortisone ± AGM 208 15.2 208 2.8
Berry, 2001 [84] paclitaxel EMP 166 15.1 p = 0.11 166 NR p = 0.08
Paclitaxel 12.9
Hudes, 1999 [61] vinblastine EMP 95 11.9 p = 0.08 98 3.7 p < 0.0004† (TTP)
Vinblastine 98 9.2 95 2.2
Iversen, 1997 [65] EMP 61 9.4 p = 0.09 60 2.2
Placebo 68 6.1 67 5.0
Johansson, 1991 [66] EMP 51 NR p = 0.23 51 NR p = 0.28
MPA 51 51
De Kernion, 1988 [67] EMP 102 NR p = NS 102 NR p = NS
Flutamide 101 101
Murphy, 1979 [68] EMP prednimustine 54 9.3 p = NS NR
prednimustine 62 9.0
*Adjusted for age, baseline hemoglobin, performance status, and alkaline phosphatase, and number of prior hormonal manipulations; †based on one-
sided significance testing.
Abbreviations: AGM – aminoglutethimide; CI – confidence interval; EMP – estramustine phosphate; HR – hazard ratio; mo – months; MPA – 
medroxyprogesterone acetate; N – number; NA – not applicable; NR – not reported; NS – non-significant; q – every; TTP – time-to-progression; 
wk(s) – week(s).Page 5 of 18
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in the docetaxel-EMP and mitoxantrone arms, respec-
tively.
Estramustine
EMP is a nor-nitrogen mustard carbamate derivative of
estradiol-17β-phosphate with estrogenic and antimicrotu-
ble effects. It is unclear how much of this agent's activity
in HRPC is due to its hormonal versus its cytotoxic effects.
Six RCTs directly examined the efficacy of EMP in HRPC
(Table 1). Three studied EMP either by comparing it to a
placebo or an oral antiandrogen [65-67], and three added
EMP to a cytotoxic agent and compared this combination
to the cytotoxic agent alone [61,68,84]. One other large
RCT comparing docetaxel-EMP to mitoxantrone-pred-
nisone could be considered to indirectly address the value
of EMP (see Docetaxel above) [63].
All six trials reported on overall survival, but none
detected improvements with EMP (Table 2). Five trials
reported TTP or PFS results; of those, one trial comparing
EMP-vinblastine to vinblastine alone reported longer TTP
with the combination (median, 3.7 versus 2.2 months,
one-sided p < 0.0004) [61]. EMP was not associated with
improved pain, performance status, or subjective
response rate in two trials reporting those data [65,68].
Hudes et al [61] reported improved pain frequency with
EMP; however, less than 50% of patients with pain com-
pleted pain questionnaires. QoL data were also collected
in that trial but did not allow comparative assessment.
The three RCTs reporting on PSA response showed higher
PSA response rates with EMP [61,65,84] (Table 3). Three
RCTs reported objective response rates [61,67,68] and
none showed improved tumor response with EMP (Table
3).
EMP was generally associated with clinically significant
higher rates and severity of gastrointestinal toxicity
(including nausea and vomiting, diarrhea, and dyspep-
sia), breast tenderness/gynecomastia, leg edema, throm-
bosis, and cardiovascular deaths [61,65-67]. The addition
of EMP to chemotherapy was also associated with a
reduced incidence and severity of neutropenia [68].
Vinorelbine
Vinorelbine is a semi-synthetic vinca alkaloid with single-
agent activity in HRPC. Abratt et al [62] randomized 414
men treated with hydrocortisone with or without
aminoglutethimide to vinorelbine or no chemotherapy
(Table 1). The primary endpoint of the trial was PFS. A
longer progression-free interval was reported with vinore-
lbine after adjustment for predetermined prognostic fac-
tors (median, 3.7 versus 2.8 months; HR = 0.71,
unadjusted two-sided p = 0.055, adjusted two-sided p =
0.005). No difference in overall survival was detected
(Table 2). Thirty-four percent of patients (n = 142) had
Table 3: Antimicrotubule trials: PSA and tumor response.









Tannock, 2004 [64] docetaxel q 3 wks prednisone 291 45 p < 0.001 141 12 p = 0.1
docetaxel q wk prednisone 291 48 p < 0.001 134 8 p = 0.6
Mitoxantrone prednisone 300 32 NA 137 7 NA
Petrylak, 2004 [63] Docetaxel EMP 309 50 p < 0.001 103 17 p < 0.30
Mitoxantrone prednisone 303 27 93 11
Abratt, 2004 [62] Vinorelbine hydrocortisone ± AGM 206 30.1 p < 0.01 68 5.9(PR) NR
hydrocortisone ± AGM 208 19.2 74 0
Berry, 2001 [84] Paclitaxel EMP 166 48 p < 0.01 NR
Paclitaxel 25
Hudes, 1999 [61] vinblastine EMP 87 25.2 p < 0.0001 30 20 (PR) p = 0.13
Vinblastine 94 3.2 33 6 (PR)
Iversen, 1997 [65] EMP 43 37.2 p = 0.001 NR
Placebo 51 2.0
Johansson, 1991 [66] EMP NR NR
MPA
De Kernion, 1988 [67] EMP NR 102 0 p = NS
Flutamide 101 1.0 (PR)
Murphy, 1979 [68] EMP prednimustine NR 54 1.9 (PR) p = NS
prednimustine 62 0
*PSA response was defined as = 50 decrease in PSA compared with baseline.
Abbreviations: AGM – aminoglutethimide; EMP – estramustine phosphate; MPA – medroxyprogesterone acetate; N – number; NA – not applicable; 
NR – not reported; NS – non-significant; PR – partial response; PSA – prostate-specific-antigen; q – every; wk(s) – week(s).Page 6 of 18
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only) and 0% were reported favoring vinorelbine (p-value
not reported) (Table 3). PSA response rates (Table 3) and
clinical benefit response (defined as improved pain, anal-
gesic score, or performance status for greater than nine
weeks) were higher with vinorelbine compared with the
control arm (30.6% versus 19.2%, p = 0.008). QoL data
were collected in the trial but were limited due to poor
patient compliance and use of a general rather than a spe-
cific prostate cancer QoL instrument; and showed no ben-
efit with vinorelbine on either global QoL or functional
subscales. More frequent severe neutropenia (26%), neu-
tropenic infection (3%), anemia (6.5%) and constipation
(3%) were observed with the addition of vinorelbine to
hydrocortisone with or without aminoglutethimide.
Anthracenedione/anthracycline-based chemotherapy
Mitoxantrone
Mitoxantrone is an anthracenedione drug with mecha-
nisms of activity similar to anthracyclines and a modest
toxicity profile. Three RCTs compared mitoxantrone com-
bined with low-dose corticosteroid to the same low-dose
corticosteroid alone without placebo [69-71] (Table 4). In
the largest trial, Kantoff et al [70] randomized 242
patients with metastatic HRPC who had undergone
AAWD to either mitoxantrone plus hydrocortisone or
hydrocortisone alone. The primary endpoint of the trial
was overall survival. Tannock et al [71] compared mitox-
antone plus prednisone to prednisone alone in 161 men
with HRPC symptomatic with pain. Pain relief was the
primary endpoint of that trial, defined by patient self-
reported pain intensity and analgesic use as recorded in an
analgesic diary. The analysis of overall survival was con-
founded by crossover to the mitoxantrone arm at the time
of cancer progression in this trial. Berry et al [69] evalu-
ated the same treatment regimens as Tannock et al in 120
men with asymptomatic HRPC using TTP as the primary
endpoint.
All three RCTs reported overall survival results but none
detected an improvement due to mitoxantrone (Table 5).
Berry et al [69] and Kantoff et al [70] both reported longer
median TTP with mitoxantrone versus control (8.1 versus
4.1 months [p = 0.018], and 3.7 versus 2.3 months [p =
0.02], respectively) (Table 5). Objective response rates
were reported in two trials [69,70] without differences
observed (Table 6). All three trials reported PSA response
rates, which were significantly higher with mitoxantrone
in one trial [69] (Table 6).
In the only trial evaluating pain, Tannock et al [71] rigor-
ously assessed palliative response through self-reported
pain scores and analgesic consumption. In the mitox-
antrone-prednisone treatment arm, 29% of patients had a
two-point reduction in pain intensity (or complete elimi-
nation of pain) on the six-point McGill-Melzack Pain
Questionnaire, maintained for three weeks apart without
an increase in analgesic use, compared with 12% of
patients treated with prednisone alone (p = 0.01). The
median duration of pain response was 43 versus 18 weeks
favoring mitoxantrone (p < 0.0001). An additional seven
patients in each arm had a decrease of ≥ 50% in analgesic
score without an increase in pain; thus, 38% of patients
treated with mitoxantrone-prednisone had palliative ben-
efit compared with 21% with prednisone alone (p =
0.025).
Two trials reported QoL data [70,71]. Tannock et al [71]
reported improved QoL with mitoxantrone-prednisone
over prednisone alone in domains related to pain, physi-
cal activity or function, constipation, and mood with the
Prostate Cancer Specific QoL Instrument and the Euro-
pean Organization for Research and Treatment of Cancer
Quality of Life Core Questionnaire (EORTC QLQ-C30).
Patients meeting the criteria for palliative response had
improvements in most QoL domains, including overall
well-being. Kantoff et al [70] also reported improved QoL
favoring mitoxantrone in the Functional Living Index:
Cancer (FLIC) emotional state and family disruption sub-
scales.
All three trials reported toxicity. Grade 3–4 neutropenia
occurred in 45% of cycles, and 63% and 48% of patients,
respectively [69-71]. Neutropenic sepsis occurred in 6.9%
and 2% of patients [69,71]. Severe symptomatic non-
hematological toxicities were rare; for example, severe
nausea and vomiting occurred in 0.5% of cycles [71]. Car-
diac dysfunction, either symptomatic or detected by
reduced LVEF, was observed in 3.8% and 5% of patients
[69,71]. No toxic deaths were observed with mitox-
antrone in any of those trials.
Doxorubicin and epirubicin
Anthracyclines are believed to exert their cytotoxic effects
primarily through the inhibition of topoisomerase-II
activity. Six RCTs examined anthracycline combinations
[72-76,88] (Table 4). Four performed in the pre-PSA era
compared doxorubicin-based cytotoxic chemotherapy
regimens to non-doxorubicin-based regimens or single
agents [74-76] or compared combined versus sequential
5-flourouracil-doxorubicin-mitomycin-C (FAM) [73].
Two trials compared anthracyclines to EMP [72,88]. The
primary endpoints of those trials were tumor response
and survival [73-76] and TTP [72].
Only one of five RCTs reporting overall survival data
reported improved survival with chemotherapy [72-
76,88] (Table 5). Laurie et al [73] randomized 142
patients to either combination chemotherapy with FAM
or sequential chemotherapy with the same drugs (mito-Page 7 of 18
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racil). Although response rates were similar between the
two arms and hematological toxicity was greater with
FAM, overall survival favored the combined FAM regimen
(median survival, 8.7 versus 7.1 months, p = 0.025). Three
trials provided comparative data on disease progression
[72,74,75]; two reported on TTP [72,74] and one reported
on PFS [75] (Table 5). Improved TTP was detected with
epirubicin and MPA compared with EMP (median, 7.6
versus 4.3 months, p = 0.013) [72].
Five trials reported on objective tumor response [73-
76,88] (Tables 6). Only two of the five trials provided sta-
tistical comparisons of those data; one detected no differ-
ence and the other reported higher response rates with
combined doxorubicin-cyclophosphamide chemother-
apy (32%) versus hydroxyurea (4%) that was of border-
line statistical significance (p = 0.05) [76]. Two of the
trials assessed a pain or palliative endpoint [76,88].
Stephens et al [76] reported that symptomatic response
rate (a composite endpoint comprising of worsening
Table 4: Mitoxantrone and anthracycline trials.
Trial N randomized/
evaluable
Treatment arms (dose) and schedule Duration
Berry, 2002 [69] 120/119 mitoxantrone (12 mg/m2) iv q 3 wks 
prednisone (5 mg) po twice daily
6 cycles
prednisone (5 mg) po twice daily
Kantoff, 1999 [70] 242/242 mitoxantrone (14 mg/m2) iv q 3 wks 
hydrocortisone (40 mg) po daily (two 
divided doses)
hydrocortisone to progression or treatment 
failure
hydrocortisone (40 mg) po daily (two 
divided doses)
Tannock, 1996 [71] 161/161 mitoxantrone (12 mg/m2) iv q 3 wks 
prednisone (5 mg) po twice daily
mitoxantrone to dose of 140 mg/m2, 
continuing on prednisone
prednisone (5 mg) po twice daily
Weissbach, 1998 [88] NR/175 epirubicin (25 mg/m2) iv q mo NR
EMP (560 mg) daily
mitomycin C (10 mg/m2) iv q mo
Anderström, 1995 [72] 149/145 epirubicin (20 mg/m2) iv q wk MPA (500 mg) 
po twice daily
epirubicin to dose of 1000 mg/m2, MPA to 
progression
EMP (12 mg/kg) po daily (two divided doses)
Laurie, 1992* [73] 145/142 In combination: 5-FU (600 mg/m2) iv q 4–5 
wks doxorubicin (30 mg/m2) iv q 4–5 wks 
mitomycin-C (10 mg/m2) iv q 4–5 wks†
to progression
In sequence: 5-FU (500 mg/m2) iv q 5 wk 
doxorubicin (50 mg/m2) iv q 3–4 wk 
mitomycin-C (12.5 mg/m2) iv q 4 wk
Saxman, 1992 [74] 103/103 cyclophosphamide (500mg/m2)‡ iv q 3 wks 
doxorubicin (50mg/m2)‡ iv q 3 wks 
methotrexate (40mg/m2)‡ iv q 3 wks
to progression, doxorubicin not to exceed 
dose of 450mg/m2
cyclophosphamide (1000 mg/m2)§iv q 3 wks
Murphy, 1988 [75] 180/152 doxorubicin (50 mg/m2) iv q 3 wks 
cyclophosphamide (500 mg/m2) iv q 3 wks
to progression
cisplatin (50 mg/m2) iv q 3 wks 5-FU (500 
mg/m2) iv q 3 wks cyclophosphamide (500 
mg/m2) iv q 3 wks
methotrexate (100 mg/m2) iv (2 divided 
doses) q 2 wks
Stephens, 1984 [76] 158/137 doxorubicin (40 mg/m2)¶iv q 3 wks 
cyclophosphamide (200 mg/m2)¶iv q 3 wks
doxorubicin to dose of 450 mg/m2, 
continuing on cyclophosphamide or 
hydroxyurea to progression
hydroxyurea (3600 mg/m2) po twice q wk
*This trial was terminated early due to declining patient accrual ; †after three courses, mitomycin-C was only given with every other course; 
‡patients who had received prior radiation therapy were give cyclophosphamide, doxorubicin, and methotrexate at doses of 400 mg/m2, 40 mg/m2, 
and 32 mg/m2, respectively; §patients who had received prior radiation therapy were given cyclophosphamide at a dose of 800 mg/m2; ¶patients 
older than 65 years and with prior bone irradiation, and marrow invasion with tumor were deemed poor risk and were randomized to a reduced 
dose of doxorubicin (20 mg/m2) and cyclophosphamide (100 mg/m2).
Abbreviations: 5-FU – 5- fluorouracil; EMP – estramustine phosphate; iv – intravenous; m2 - meters squared; mg – milligrams; mo – month; MPA – 
medroxyprogesterone; N – number; po – per oral; q – every; wk(s) – week(s)Page 8 of 18
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bicin plus cyclophosphamide compared with hydroxyu-
rea (26% versus 13%, p = 0.048) but the duration of that
response was not significantly different between the two
groups (p = 0.62). The second trial [88] reported compa-
rable rates of pain relief (undefined) among patients
treated with epirubicin (49%), mitomycin C (48%), and
EMP (42%). None of the six trials reported QoL data.
Other cytotoxic agents
Four trials studied other chemotherapy agents
[75,77,78,88] (Table 7). The National Prostatic Cancer
Project (NPCP) randomized 189 men with clinically pro-
gressing HRPC to either single-agent cisplatin, methotrex-
ate, or EMP [78]. In a successor trial, 180 patients were
randomized to either single-agent methotrexate, combi-
nation cyclophosphamide-5-fluorouracil-cisplatin, or
cyclophosphamide-doxorubicin [75]. Objective response
by NPCP criteria was the primary endpoint of both trials.
Newling et al [77] compared mitomycin C with EMP in
171 randomized patients with TTP and overall survival as
primary endpoints. All three trials were completed during
the pre-PSA era. Weissbach et al [88] randomized 175
patients to mitomycin C, epirubicin, or EMP.
All four trials reported data on overall survival
[75,77,78,88], but none reported differences between trial
arms. Two trials reported on disease progression [75,77]
and no differences were detected. Improved time-to-treat-
ment failure was reported with mitomycin C compared
Table 5: Mitoxantrone and anthracycline trials: survival outcomes.
Trial Treatment arms Overall survival Progression-free survival or TTP
N Median (mo) Statistical 
comparison
N Median (mo) Statistical 
comparison
Berry, 2002 [69] mitoxantrone 
prednisone
56 23 p = 0.48 56 8.1 p = 0.018 (TTP)
prednisone 63 19 63 4.1
Kantoff, 1999 [70] mitoxantrone 119 12.3 p = 0.77 119 3.7 p = 0.02 (TTP)
hydrocortisone 123 12.6 123 2.3
Tannock, 1996 [71] mitoxantrone 
prednisone
80 NR p = 0.27 NR
prednisone 81
Weissbach, 1998 [88] epirubicin 61 NR by 
treatment 
group
61 NR by 
treatment 
group
"TTF was longer with 
mitomycin C vs. EMP (p 
= 0.037); and vs. 
epirubicin (p = 0.039)
EMP 54 54
mitomycin C 60 60
Anderström, 1995 [72] epiribucin MPA 73 11.5 p = NS 73 7.6 p = 0.013 (TTP)
EMP 72 9.5 72 4.3
Laurie, 1992 [73] 5-FU doxorubicin 
mitomycin C 
(combined)











9.5 6 p = 0.93 p = 
0.51 p = 0.7 
(unstratified)
50 6.2* p = 0.07 (TTP)
cyclophosphamide 26 high 
PS 27 
low PS
9 5 53 4.4*
Murphy, 1988 [75] doxorubicin 
cyclophosphamide





Stephens, 1984 [76] doxorubicin 
cyclophosphamide
68 6.8 p = NS NR
hydroxyurea 69 7
*Median values include only patients with partial response or stable disease (n was not reported).
Abbreviations: 5-FU – 5- fluorouracil; EMP – estramustine phosphate; mo – months; MPA – medroxyprogesterone; N – number; NR – not 
reported; NS – non-significant; PS – performance status; TTF – time-to-treatment failure; TTP – time-to-progression; vs – versus.Page 9 of 18
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als reporting symptomatic or pain response identified no
differences [78]. Three trials [75,78,88] reported tumor
response data and no differences were observed. One trial
collected QoL data, but it was of limited value due to
missing data [77].
Non-cytotoxic agents
Five non-cytotoxic agents, including liarozole, suramin,
atrasentan, prinomastat, and APC8015 have been investi-
gated in RCTs in HRPC (Table 8) [79-83,85-87]. Liarozole
is thought able to promote the differentiation of malig-
nant cells by increasing intracellular levels of retinoic acid.
Debruyne et al [83] randomized 321 patients to either
liarozole or cyproterone acetate. Suramin is a highly
charged polysulfonated napthylurea with antineoplastic
activity of uncertain mechanisms and adrenolytic effects.
Two recent, large RCTs have studied suramin in men with
HRPC. In a placebo-controlled trial, Small et al [82] stud-
ied the effects of suramin plus hydrocortisone to hydro-
cortisone alone in men with HRPC and pain requiring
opioid analgesics. The primary endpoint was pain
response. A subsequent RCT compared three different
doses of suramin and evaluated PSA response as the pri-
mary endpoint [81]. Atrasentan is an orally bioavailable
endothelin A antagonist. Two large RCTs have studied
atrasentan in comparison to placebo in men with HRPC
[79,85]. The matrix metalloprotease inhibitor prinomas-
tat has been combined with mitoxantrone-prednisone
and compared with placebo [87]. APC8015 is a cellular
therapy consisting of autologous peripheral blood mono-
nuclear cells enriched for dendritic cells and pulsed with a
prostatic acid phosphatase-GM-CSF construct. APC8015
has also been compared with placebo in men with HRPC
[86].
Four of the seven trials of non-cytotoxic agents reported
overall survival results, and none reported differences in
overall survival between treatment arms (Table 9) [80-
83,87]. Reduced mortality was reported when liarozole
was compared with cyproterone acetate after an adjust-
ment for prognostic factors by Cox multivariate regression
analysis (HR = 0.74 [95% CI, 0.56–0.99], p = 0.039) [83].
All eight trials reported on a disease-progression outcome;
four trials reported TTP [79,82,85,86], three reported on
PFS [81,83,87] and one reported failure-free survival data
Table 6: Mitoxantrone and anthracycline trials: PSA and tumor response.
Trial Treatment arms PSA response* Tumor response









Berry, 2002 [69] mitoxantrone prednisone 56 48† p = 0.007 8 25 (PR) p = NR
prednisone 63 24† 9 22 (PR)
Kantoff, 1999 [70] mitoxantrone hydrocortisone 96 18.7 p = 0.41 116 7 (PR) p = 0.38
hydrocortisone 91 14.3 118 4 (PR)
Tannock, 1996 [71] mitoxantrone prednisone 57 33 p = 0.11 NR
prednisone 54 22
Weissbach, 1998 [88] mitomycin C NR 60 22 NR
epirubicin 61 11
EMP 55 9
Anderström, 1995 [72] epiribucin MPA NR NR
EMP
Laurie, 1992 [73] 5-FU doxorubicin mitomycin-C 
(combined)
NR 70 14 NR
5-FU doxorubicin mitomycin-C 
(sequential)
72 18
Saxman, 1992 [74] cyclophosphamide doxorubicin 
methotrexate
NR 16 18.8 (PR) NR
cyclophosphamide 16 6 (PR)
Murphy, 1988 [75] doxorubicin cyclophosphamide NR 54 1 (PR) p = NS
cisplatin 5-FU cyclophosphamide 46 0
methotrexate 52 0
Stephens, 1984 [76] doxorubicin cyclophosphamide NR 19 32 p = 0.05
hydroxyurea 24 4
*PSA response was defined as e50% decrease in PSA compared with baseline; †PSA response with stabilization or improvement of performance 
status for at least 2 weeks.
Abbreviations: 5-FU – 5-fluorouracil; EMP – estramustine phosphate; N – number; NR – not reported; NS – non-significant; PR – partial response; 
PSA – prostate-specific antigen.Page 10 of 18
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significant differences favoring the experimental treat-
ment [80,82]. TTP was improved with suramin-hydrocor-
tisone compared with placebo-hydrocortisone (relative
risk = 1.51 [95% CI, 1.22–1.85], two-sided p = 0.0003)
[82], but was not affected by suramin schedule in another
trial [81]. Tumor response data were reported in three tri-
als [80-82] (Table 10), of which only one detected signif-
icant differences between trial arms [80]. PSA response
rates were reported in seven trials [79,81-83,85-87]; four
of those detected statistically significantly higher response
rates with the experimental therapy [79,82,83,85] (Table
10).
Three trials reported pain or symptomatic response data
[80,82,83,86]. The mean best change in pain and analge-
sic use score compared with baseline was improved with
liarozole compared with cyproterone acetate (mean
reduction 0.4 versus 0.2, p = 0.026) [83]. Small et al [82]
assessed palliative response to suramin with self-reported
pain scores and opioid analgesic use using two methods.
For the first method, average worst pain scores (during the
previous 24 hours) measured with the Brief Pain Inven-
tory (BPI) and opioid analgesic consumption were
assessed in each treatment group and compared with
baseline at six weeks and at the end of treatment. Suramin
was superior to placebo for pain reduction at both six
weeks and the end of study; no statistically significant dif-
ferences in narcotic analgesic consumption were
observed. For the second method, pain response was
measured and defined either by a three-point reduction
(or complete elimination) of worst pain on the BPI
(maintained for at least three weeks) with a <16% increase
in opioid analgesic use or by a ≥ 33% (minimum 5 mg)
reduction in opioid analgesic use with a two-point or less
increase in pain. More patients in the suramin group had
pain response compared with placebo (43% versus 28%,
p = 0.001), and the duration of pain response was signifi-
cantly higher (median 240 versus 69 days, two-sided p =
0.0027). Performance status measured by the Revised
Rand Functional Limitations Scale was not improved with
suramin compared with placebo. Three trials assessed
QoL outcomes [79,82,83] and none reported differences.
Liarozole was associated with increased rates of skin tox-
icity, nausea and vomiting, and fatigue [83]. In compari-
son to placebo, suramin was associated with more
frequent mild to moderate rash (57% versus 13%) and
severe edema and anemia (both <5%) [82]. Higher rates
of severe toxicities were seen with high-dose suramin,
including neutropenia, anorexia, cardiac dysrhythmias,
and neuromotor toxicity [81]. Prinomastat was associated
with increased rates of mild to moderate musculoskeletal
effects including arthralgia, joint stiffness and swelling,
and, rarely, contracture compared with placebo [87].
Atrasentan was associated with increased rates of mild to
moderate peripheral edema, rhinitis, headache, hypoten-
sion, anemia, and weight gain compared with placebo
[79].
Discussion
The diagnosis and clinical management of HRPC has
undergone radical changes over the past decade, along
with the design and methodology of clinical trials. A
"stage migration" has occurred due to the ability of PSA
testing to detect biochemical evidence of androgen inde-
pendence before other clinical symptoms or signs become
apparent. In the pre-PSA era, men with HRPC enrolled in
RCTs were often symptomatic and extensively pre-treated
with palliative radiotherapy. Androgen levels influence
tumor growth in HRPC, and differences in or lack of con-
trol of ADT used in trial subjects might affect outcomes.
Table 7: Other chemotherapy trials.
Trial N randomized/Evaluable Treatments (dose) and schedule Duration
Weissbach, 1998 [88] NR/175 epirubicin (25 mg/m2) iv q mo NR
EMP (560 mg) daily
mitomycin C (10 mg/m2) iv q mo
Newling, 1993 [77] 171/161 mitomycin-C (15 mg/m2) iv q 6 wks to progression
EMP (560 to 700 mg)* po daily
Murphy, 1988 [75] 180/152 doxorubicin (50 mg/m2) iv q 3 wks cyclophosphamide (500 mg/m2) iv q 3 
wks
to progression
cisplatin (50 mg/m2) iv q 3 wks 5-FU (500 mg/m2) iv q 3 wks 
cyclophosphamide (500 mg/m2) iv q 3 wks
methotrexate (100 mg/m2) iv (2 divided doses) q 2 wks
Loening, 1983 [78] 189/158 methotrexate (100 mg/m2) iv (two divided doses) q wk 12 wks
cisplatin (60 mg/m2) iv (d1,4,21,24), then once monthly
EMP (600 mg/m2) po daily (3 divided doses)
*Dose of estramustine escalated to 700 mg if 560 mg dose was tolerated for two weeks.
Abbreviations: 5-FU – 5- fluorouracil; d – day; EMP – estramustine phosphate; iv – intravenous; m2 - meters squared; mg – milligrams; mo – month; 
N – number; NR – not reported; po – per oral; q – every; wk(s) – week (s).Page 11 of 18
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(LHRH)-agonist use has become much more prevalent
over the past decade, replacing estrogens and reducing the
use of bilateral orchiectomy. As well, the AAWD syn-
drome has been identified as a potential confounder of
clinical and biochemical response in HRPC [89]. With-
drawal of oral antiandrogens and maintenance of ADT
were required for entry onto the largest clinical trials
[63,64,70,71] discussed in this review. Generalizability,
changes in use of androgen deprivation therapy, and the
validity of trial endpoints need to be considered in the
interpretation and weighting of the evidence provided by
clinical trials in HRPC.
Typically, men with HRPC have skeletal metastases that
cannot be conventionally assessed for objective response
to anticancer therapy. As a result, drug trials have used a
number of different primary endpoints. The identification
of benefits from non-hormonal drug therapy only became
clear over the past 15 years with the emergence first of val-
idated symptom and quality of life instruments, then the
availability of PSA as a tumor marker, and finally the abil-
ity to conduct randomized trials large enough to ade-
quately assess survival benefits. As the purpose of this
review was to inform clinical practice, endpoints unequiv-
ocally associated with patient benefit or harm were
emphasized, as were RCTs of sufficient power to assess
these.
Early RCTs studying several single-agent and combination
chemotherapy regimens compared with other single-
agent chemotherapy controls showed evidence of modest
anti-tumor activity generally accompanied by increased
toxicity. Interpretation of the results of these trials was
limited by their sample sizes and lack of validated psycho-
metric tools to ascertain palliative treatment benefits. Tan-
nock et al [71] established mitoxantrone-prednisone as a
standard palliative therapy for men with HRPC sympto-
matic with pain. Two trials [69,70] subsequently con-
firmed that mitoxantrone also improved TTP compared to
initial corticosteroid therapy alone. The lack of toxicity in
those trials was notable, with no toxic deaths and few seri-
ous hematological and non-hematological side effects.
Cardiomyopathy was observed in ≥ 5% of patients in
Table 8: Non-cytotoxic trials.
Trial N randomized/
evaluable
Treatments (dose) and schedule Duration
Carducci, 
2004 [85]




288/288 atrasentan (2.5 mg) po daily to progression








390/390 suramin (3.192 mg/m2)* iv 3 cycles (12 weeks)
suramin (5.320 mg/m2)* iv
suramin (7.661 mg/m2)* iv
Ahmann, 
2001 [87]
553/406† prinomastat (5 mg) po twice daily mitoxantrone (12 mg/m2) iv q 3 
wks prednisone (5 mg) po twice daily
NR
prinomastat (10 mg) po twice daily mitoxantrone (12 mg/m2) iv q 3 
wks prednisone (5 mg) po twice daily




460/458 suramin d1: 1000 mg/m2 2-hr iv d2-5: 400 mg/m2, 300 mg/m2, 250 
mg/m2, and 200 mg/m2 iv, respectively d8,11,15,19: 275 mg/m2 iv for 
2 wks d22,29,36,43,50,57,64,71,78: 275 mg/m2 iv wks 4–12 
hydrocortisone (40 mg) po daily
to progression or unacceptable 
toxicity
hydrocortisone po daily placebo
Debruyne, 
1998 [83]
321/321 liarozole (300 mg) twice daily to progression or unacceptable 
toxicity
CPA (100 mg) twice daily
*Doses of suramin decreased over 10 weeks; all patients received hydrocortisone at a dose of 25 mg orally each morning and 15 mg orally each 
evening; †interim results available for 406/553 patients.
Abbreviations: CPA – cyproterone acetate; d – day; DES – diethylstilbestrol diphosphate; g – grams; hr – hour; iv – intravenous; m2 - meters 
squared; mg – milligram; N – number; NR – not reported; po – per oral; q – every; wk(s) – week(s); × – times.Page 12 of 18
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elbine, along with a modest benefit in clinical benefit
response [65]. A number of agents with novel mecha-
nisms of anti-tumor activity have been studied in HRPC;
and although activity and some benefits have been
observed, data from RCTs has not yet established any of
these agents as standard therapeutic options for HRPC.
The strategy of adding EMP to chemotherapy has also
been explored, and PSA response and disease control
appear modestly improved [64,68,87]. However, overall
survival is not clearly increased, and EMP is associated
with adverse effects that include thrombosis and cardio-
vascular toxicity [61,63,65,84].
Improvement in overall survival has been reported with
docetaxel given every three weeks in comparison with
mitoxantrone-prednisone in two large, well-conducted
RCTs [63,64]. Docetaxel-prednisone given on a weekly
schedule was not clearly associated with improved overall
survival [64]. These trials also reported evidence of
improved PFS, palliative response, and/or objective
response with all the docetaxel regimens studied.
Docetaxel-prednisone (without estramustine) was associ-
ated with more frequent mild toxicities, similar rates of
serious toxicities, and better QoL than mitoxantrone-
prednisone. Based on this evidence, docetaxel given every
third week with either daily prednisone or EMP appears to
be the most effective drug treatment tested in RCTs for
men with HRPC and metastases; however, indirect com-
parison suggests the latter regimen may be associated with
more frequent and severe toxicities than the former.
Conclusion
Docetaxel-based chemotherapy given every three weeks
was the only treatment that demonstrated an overall sur-
vival benefit in men with HRPC. Most men receiving
Table 9: Non-cytotoxic trials: survival outcomes.
Trial Treatment arms Overall survival Progression-free survival or TTP or FFS
N Median (mo) Statistical 
comparison
N Median (mo) Statistical 
comparison




Carducci, 2003 [79] atrasentan 10 mg NR 89 6.5 p = 0.13 (TTP)
atrasentan 2.5 mg 95 6.4 p = 0.29 (TTP)
placebo 104 4.9 NA




Small, 2002 [81] suramin (3.192 g/m2) 128 16 p = 0.49 128 NR p = NS
suramin (5.320 g/m2) 124 14 124
suramin (7.661 g/m2) 120 13 120
Ahmann, 2001 [87] prinomastat (5 mg) 
mitoxantrone 
prednisone
134 15.1 p = NS 134 6 p = NS
prinomastat (10 mg) 
mitoxantrone 
prednisone
134 14.7 134 4.7
mitoxantrone 
prednisone placebo
138 14.8 138 6
Small, 2000 [82] suramin hydrocortisone 228 10.2 p = NS 228 NR RR for TTP = 1.51
(95% CI, 1.22–1.85)
p = 0.0003
placebo hydrocortisone 230 10 230
Debruyne, 1998 [83] liarozole 160 10.3 p = 0.52
HR = 0.74*
(95% CI, 0.56–0.99) 
p = 0.039
160 4.9 p = NS
CPA 161 10.3 161 4.6
*Adjusted for performance status, hemoglobin, baseline PSA, alkaline phosphatase, and duration of response.
Abbreviations: CI – confidence interval; CPA – cyproterone acetate; DES – diethylstilbestrol; FFS – failure-free survival; HR – hazard ratio; m2 - 
meters squared; mg – milligrams; mo – months; N – number; NA – not applicable; NR – not reported; NS – non-significant; RR – relative risk; TTP 
– time-to-progression.Page 13 of 18
(page number not for citation purposes)
BMC Cancer 2006, 6:112 http://www.biomedcentral.com/1471-2407/6/112docetaxel had metastases, so the timing of docetaxel ther-
apy in men without metastases should not only be care-
fully considered but also studied further in clinical trials.
Expectant management, trials of secondary hormonal
manipulations, and/or participation in clinical trials of
investigational agents before chemotherapy are also rea-
sonable alternatives for many men with HRPC on an indi-
vidualized basis. In the largest randomized trials, men
continued on gonadal androgen suppression and discon-
tinued the use of oral antiandrogens, and these maneu-
vers are recommended for men planned to receive
chemotherapy. Use of EMP in combination with other
cytotoxic agents is probably not worthwhile due to the
increased risk of clinically important toxicities without
clear evidence of improved survival or palliation. Mitox-
antrone-prednisone and weekly docetaxel-prednisone are
associated with symptom palliation and improved disease
control without improved overall survival, and can be
considered clinical alternatives to docetaxel given every
three weeks.
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